Artiva Biotherapeutics Stock
Artiva Biotherapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Fred Aslan
- Employees
- 115
- Market cap
- $286 M
- IPO
- 19/07/2024
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK…
Artiva Biotherapeutics stock: price history
1D
-3.5%
1W
-15.7%
1M
-32.0%
6M
-53.4%
YTD
+36.4%
1Y
+111.2%
2Y
-57.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~20% weaker price swings than usual
Artiva Biotherapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 18/08/2026.
Ask the agents about Artiva Biotherapeutics
Analyst assessment of Artiva Biotherapeutics
PRICE TARGET LOW
US$35.00
CONSENSUS
US$37.50
MEDIAN
US$37.50
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 02/10/2026
Artiva Biotherapeutics stock metrics
P/E
-1.77
P/B
0.66
EV/EBITDA
0.06
RETURN ON EQUITY
-7.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
39.9%
FLOAT SHARES
19,530,137
AVG. DAILY VOLUME (30D)
493,517
Insider transactions (SEC)
Aslan Fred
Aslan Fred
Banerjee Subhashis
Bush Jennifer
Horan Christopher
Attention
Price since yesterday: -3.5%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Artiva Biotherapeutics stock
What does Artiva Biotherapeutics do?
Artiva Biotherapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Fred Aslan, the company employs around 115 people.
The IPO was on 19/07/2024; the stock trades on NASDAQ under the ticker ARTV.
What do analysts say about Artiva Biotherapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is US$37.50, ranging from US$35.00 to US$40.00, with a median of US$37.50.
This is an external assessment, not a statement by Market Jury.
When does Artiva Biotherapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -20% stronger than usual.
Does Artiva Biotherapeutics pay a dividend?
No, Artiva Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to Artiva Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Artiva Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Artiva Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.